SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is trending amid reports of snags and delays in its anticipated Siri AI integration, sparking community debate between those capitalizing on the downside and others dismissing the news as an overreaction, pointing to strong iPhone sales in China.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase is trending with intense community debate and high volatility ahead of its imminent earnings report. Bears are concerned about a potential miss following Robinhood's crypto revenue decline and recent downgrades, while bulls view the stock as deeply oversold with a low P/E, anticipating a significant post-earnings rebound.

Fastly, Inc. provides real-time content delivery network services. It offers edge compute, edge delivery, edge security, edge applications like load balancing and image optimization, video on demand, and managed edge delivery. The company was founded by Artur Bergman, Tyler McMullen, Simon Wistow, and Gil Penchina in March 2011 and is headquartered in San Francisco, CA.

Fastly Inc - Ordinary Shares - Class A

Fastly Inc

Fastly is trending after a surprisingly strong earnings report showcased record revenue, gross margin, and profitability, with the company highlighting AI as a major tailwind for its edge computing and security services. This has sparked intense community discussion about its re-rating as an AI play, attracting bulls anticipating further upside and a potential short squeeze, while others warn of a quick profit-taking pullback.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin (APP) is trending sharply lower despite reporting strong quarterly earnings and upbeat guidance, fueling community frustration and calls of market manipulation as the broader software sector faces a negative sentiment, leaving many to question the disconnect from its robust fundamentals.

BlackRock Institutional Trust Company N.A. - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

TLT is trending as the community debates the implications of Kevin Warsh's nomination for Fed Chair, with varied perspectives on future interest rate policy and balance sheet strategy. This uncertainty, coupled with recent mixed economic data like softer retail sales and downward revisions to job numbers, is driving conversation around potential earlier rate cuts and TLT's appeal as a flight-to-safety asset.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy`s Co

Wendy's (WEN) is trending due to widespread reports of a potential takeover bid, which has ignited fervent community discussions about its perceived undervaluation, high dividend yield, and significant short interest. Investors are actively debating the company's ongoing turnaround efforts and the potential for a short squeeze as they await further corporate developments and the upcoming earnings report.

Cisco Systems, Inc. engages in the design, manufacture, and sale of Internet Protocol-based networking products and services related to the communications and information technology industry. The firm operates through the following geographical segments: the Americas, EMEA, and APJC. Its products include the following categories: Secure, Agile Networks, Internet for the Future, Collaboration, End-to-End Security, Optimized Application Experiences, and Other Products. The company was founded by Sandra Lerner and Leonard Bosack in 1984 and is headquartered in San Jose, CA.

Cisco Systems, Inc.

Cisco Systems is trending after reporting strong earnings and raising its full-year guidance, primarily fueled by a significant surge in AI infrastructure orders from hyperscalers. Despite some market reaction to margin pressure, the community is actively discussing its pivotal role in the AI buildout, leading to analysts raising price targets and many viewing recent dips as a buying opportunity.

Braiin Ltd. is an Australian technology company, which engages in developing a precision agriculture technology platform that provides farm management services. It operates through the following geographical segments: Australia, Sri Lanka, and U.S.A. The company was founded by Natraj Balasubramanian and Darren McVean on July 4, 2022 and is headquartered in Subiaco, Australia.

Braiin Ltd

Braiin Ltd (BRAI) is trending as a new IPO experiencing extreme volatility and massive percentage gains on low trading volume, leading to community discussion around its potential for quick profits balanced with significant caution regarding liquidity and sustainability.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is experiencing a significant sell-off following its recent earnings report, primarily driven by weaker cryptocurrency trading revenue. Despite the dip, community sentiment is sharply divided, with bulls pointing to strong growth in non-crypto segments like prediction markets and subscriptions, while bears remain concerned about its correlation to the crypto market and overall valuation.

Block, Inc. engages in creating ecosystems for distinct customer audiences. It operates through the Square and Cash App segments. The Square segment provides payment services, software solutions, hardware, and financial services to sellers. The Cash App segment includes the financial tools available to individuals within the mobile Cash App, including peer-to-peer payments, bitcoin and stock investments. It also includes Cash App Card, which is linked to customer stored balances that customers can use to pay for purchases or withdraw funds from an ATM. The company was founded by Jack Patrick Dorsey and James Morgan McKelvey in February 2009 and is headquartered in Oakland, CA.

Block Inc - Ordinary Shares - Class A

Block Inc

Block (XYZ) is trending following its Investor Day, where management presented an accelerated profit growth outlook through 2028 and authorized a substantial $5 billion share buyback program. This news has sparked community discussion and optimism for a potential turnaround, contrasting with prior frustrations over the stock's performance, its Bitcoin exposure, and broader struggles in the fintech sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Novavax (NVAX) Rises As Market Takes a Dip: Key Facts

Novavax (NVAX) reached $8.97 at the closing of the latest trading day, reflecting a +2.51% change compared to its last close.

<ul class="summary-bullets"><li>The regulator said the Phase 3 study comparator did not reflect the “best-available standard of care,” though it raised no safety or efficacy concerns.</li><li>Moderna said the refusal conflicts with prior FDA guidance that allowed the comparator.</li><li>CEO Stephane Bancel will seek clarity through a requested Type A meeting.</li></ul><p>Shares of Moderna, Inc. (MRNA) fell about 9% in after-hours trading on Tuesday after the company said U.S. regulators declined to accept its application for review of its experimental seasonal influenza vaccine, marking another regulatory setback for the vaccine maker.</p><p>In the regular session,&nbsp;<a href="https://stocktwits.com/symbol/MRNA">MRNA stock</a> rose 0.1% to $41.99. The regulatory setback also lifted shares of rival Novavax, which is developing a protein-based seasonal influenza vaccine candidate, with the stock rising more than 1% in after-hours trading.</p><h2 class="st-heading-2"><strong>FDA Rejects Moderna Flu Vaccine Filing</strong></h2><p>Moderna said the U.S. Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER) issued a refusal-to-file letter for the biologics license application (BLA) of its investigational flu vaccine, mRNA-1010, and will not initiate a review, despite the company using a priority review voucher.</p><p>The letter said the application lacked an “adequate and well-controlled” study using a comparator reflecting the “best-available standard of care,” and did not raise any safety or efficacy concerns.</p><p>The BLA includes two positive Phase 3 studies enrolling 43,808 participants. One showed a stronger immune response and a favorable safety profile compared with a high-dose flu shot in adults aged 65 and older, while the other showed higher effectiveness than a standard-dose vaccine in adults aged 50 and older. Moderna said the FDA reviewed and cleared both trial designs before the studies began.</p><p>The decision was signed by Vinay Prasad, who is also known for halting broader access to Sarepta Therapeutics’ gene therapy Elevidys, drawing backlash over access to the only approved treatment for Duchenne muscular dystrophy.</p><h2 class="st-heading-2"><strong>Moderna Flags Inconsistency In FDA Feedback</strong></h2><p>Moderna said the refusal conflicted with earlier written guidance from the FDA’s CBER. In April 2024, regulators said using a licensed standard-dose influenza vaccine as the comparator would be acceptable, while recommending a high-dose or an adjuvanted vaccine for participants&nbsp;aged 65 and older. The company said no objections or clinical holds were raised after the Phase 3 protocol was submitted or before the trial began in September 2024.</p><p>After the Phase 3 study met all pre-specified endpoints, Moderna said it provided additional comparator analyses requested during an August 2025 pre-submission meeting, including data from a separate Phase 3 trial comparing a licensed high-dose flu vaccine with a comparator. Moderna said the FDA did not signal it would refuse to review the application.</p><p>CEO Stephane Bancel said the decision&nbsp;was based on no safety or efficacy issues and that the company would seek clarity on the path forward.</p><h2 class="st-heading-2"><strong>Moderna Seeks Type A FDA Meeting</strong></h2><p>Moderna said it has requested a Type A meeting with CBER. The company said mRNA-1010 has been accepted for review in the European Union, Canada and Australia, with additional country submissions planned for 2026. It expects the earliest potential approvals outside the U.S. in late 2026 or early 2027 and said the FDA decision will not affect its 2026 financial guidance.</p><h2 class="st-heading-2"><strong>Regulatory Backdrop Weighs On Vaccine Makers</strong></h2><p>The FDA decision adds to regulatory uncertainty facing vaccine manufacturers in the U.S. Last month, Bancel told&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2026-01-22/moderna-mrna-curbs-investment-in-vaccine-trials-due-to-us-backlash">Bloomberg</a> at the World Economic Forum in Davos that Moderna does not plan to invest in new late-stage vaccine trials without clearer access to the U.S. market, citing regulatory delays and reduced support for immunization programs.</p><p>In December, a leaked internal email from Prasad surfaced, asserting that COVID-19 vaccines were linked to at least 10 pediatric deaths, a claim experts said lacked supporting data. Moderna has been seeking to diversify beyond its COVID-19 vaccines and is focusing on personalized cancer vaccines, while also looking for external funding partners to advance certain late-stage vaccine programs.</p><h2 class="st-heading-2"><strong>How Did Stocktwits Users React?</strong></h2><p>On Stocktwits, retail sentiment for MRNA was ‘bearish’ amid ‘low’ message volume.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/mrna_ss_png_b80d531229.webp" alt="mrna ss.png" width="969" height="143"><figcaption>MRNA sentiment and message volume as of February 10 | Source: Stocktwits</figcaption></figure><p>One bearish user said, “So glad I sold at $49 this time round. This is going to struggle to stay solvent soon.”</p><p><stembedurl>https://stocktwits.com/TopazFrenzy/message/644621591</stembedurl></p><p>Another user called the company a “Great short!” and expects the stock to trade in the range of $20-$28.</p><p><stembedurl>https://stocktwits.com/Tradebub/message/644623819</stembedurl></p><p>MRNA stock has risen 32% over the past 12 months.</p><p>See Also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/mrna-vs-nvax-which-vaccine-stock-is-wall-street-more-bullish-on-right-now/cmUzkZbR4QI">MRNA Vs NVAX: Which Vaccine Stock Is Wall Street More Bullish On Right Now?</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

In this photo illustration, Moderna’s logo is displayed on a smartphone with an economic stock exchange index graph in the background. (Photo Illustration by Budrul Chukrut/SOPA Images/LightRocket via Getty Images)

Why Did Moderna Stock Tumble Nearly 10% After Hours Today?

The FDA’s CBER issued a refusal-to-file letter for Moderna’s flu vaccine mRNA-1010.

Equity

Allianz Asset Management GmbH Acquires 872,987 Shares of Novavax, Inc. $NVAX

Allianz Asset Management GmbH lifted its holdings in Novavax, Inc. (NASDAQ:NVAX - Free Report) by 162.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities...

Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know  

Zacks.com users have recently been watching Novavax (NVAX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Why Novavax (NVAX) Dipped More Than Broader Market Today

Novavax (NVAX) concluded the recent trading session at $8.37, signifying a -3.68% move from its prior day's close.

Novavax (NASDAQ:NVAX) Lowered to Sell Rating by Wall Street Zen

Wall Street Zen cut Novavax from a "hold" rating to a "sell" rating in a research report on Saturday...

Here's Why Novavax (NVAX) Fell More Than Broader Market

In the latest trading session, Novavax (NVAX) closed at $9.22, marking a -6.07% move from the previous day.

Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It

Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Novavax (NVAX) Stock Dips While Market Gains: Key Facts

In the latest trading session, Novavax (NVAX) closed at $9.71, marking a -1.97% move from the previous day.

<ul class="summary-bullets"><li>Analysts see greater upside in Novavax, while Moderna carries a ‘Hold’ rating despite stronger gains over the past year.</li><li>Moderna was in focus after updated cancer vaccine data, while Novavax drew attention following its Pfizer licensing deal.</li><li>Retail sentiment on Stocktwits was 'extremely bullish' for both stocks, with message activity sharply higher over the past year.</li></ul><p>Wall Street is&nbsp;a bit&nbsp;split on Moderna and Novavax, with analysts favoring upside in one name even as the other has outperformed over the past year.</p><h2 class="st-heading-2"><strong>Analysts Favor Novavax Over Moderna</strong></h2><p>Koyfin data shows analysts assigning greater upside to Novavax than Moderna based on consensus price targets.</p><p>Moderna shares were last trading around $49.81 on Wednesday, but Wall Street’s expectations remain cautious. The stock’s average 12-month price target is $37.40, a 25% downside from current levels. Among the 24 analysts covering the company, the overall view sits at ‘Hold’, with two ‘Strong Buy’, two ‘Buy’, 17 ‘Hold’, one ‘Sell’, and two ‘Strong Sell’ ratings, giving Moderna an overall ‘Hold’ rating.</p><p>Meanwhile, Novavax last closed at $9.9 on Wednesday, and analysts see room for gains. The stock’s average 12-month price target of $12.89 points to a 30% upside&nbsp;from current levels. Among the nine analysts tracking the company, five rate it ‘Buy’, one ‘Hold’, one ‘Sell’, and two ‘Strong Sell’, giving Novavax an overall ‘Buy’ rating.</p><p>Over the past 12 months,&nbsp;<a href="https://stocktwits.com/symbol/NVAX">Novavax shares</a>&nbsp;have been up about 12%, while&nbsp;<a href="https://stocktwits.com/symbol/MRNA">Moderna</a> has gained roughly 39%.</p><h2 class="st-heading-2"><strong>Moderna Faces Analyst Caution</strong></h2><p>On Tuesday,&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/moderna-stock-still-worth-37-less-after-cancer-vaccine-data-bof-a-s-new-price-target-keeps-retail-traders-cautious/cmUDauIR4OV">Bank of America Securities raised its price target to $27 from $24</a> while keeping an ‘Underperform’ rating, implying a 37% downside based on the stock’s prior close near $43.</p><p>The update followed the release of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/moderna-shares-rise-on-five-year-follow-up-takeaways-for-skin-cancer-vaccine/cmUuq4QR4OT">five-year follow-up data</a> for Moderna’s personalized cancer vaccine Intismeran Autogene, developed with Merck and used alongside Keytruda in patients with high-risk melanoma. Moderna and Merck said patients receiving the combination showed a 49% lower risk of cancer recurrence or death compared with Keytruda alone.&nbsp;</p><p>Earlier this month, UBS downgraded the stock to ‘Neutral’ from ‘Buy’ and cut its price target to $34 from $40, implying about 32% downside from its last close.&nbsp;</p><p>Moderna expects regulatory approvals this year for a standalone flu vaccine and a COVID-19/flu combination shot, though not in time for the 2026 respiratory season, with a potential boost in 2027. The company also expects key trial data in 2026, including late-stage norovirus results and mid-stage melanoma data.&nbsp;</p><h2 class="st-heading-2"><strong>Novavax In Focus</strong></h2><p>This week, Novavax&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-nvax-stock-rising-premarket-pfizer-matrix-m-deal/cmUumrjR4aq">signed a non-exclusive licensing deal with Pfizer</a> for up to two disease areas using its Matrix-M adjuvant. The deal includes a $30 million upfront payment, as well as the possibility of up to $500 million in development and sales milestones, and tiered royalties in the high mid-single-digit range.&nbsp;</p><p>That deal followed Novavax handing over U.S. and European rights to its Covid-19 vaccine candidate Nuvaxovid to Sanofi in November for undisclosed upfront payments and possible milestones. The deal also opens the door&nbsp;to future royalties. Novavax also has deals with Takeda and the Serum Institute of India.</p><p>Novavax has pushed its profitability target to 2028 as Covid-19 vaccine demand remains under pressure, while activist investor Shah Capital, which holds about 8.3%, has&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/novavax-stock-faces-retail-backlash-as-shah-capital-warns-of-proxy-fight-and-presses-for-a-sale/cLPBFk7REdt">urged the board to review strategic alternatives</a>, including a potential sale.</p><h2 class="st-heading-2"><strong>Regulatory Backdrop</strong></h2><p>Uncertainty over regulatory approval also looms for both companies. Shares of Moderna and Novavax fell in December after an FDA memo to staff, which did not name a manufacturer, warned of safety problems with vaccines that could lead to tougher approval standards.</p><p>Novavax’s COVID-19 vaccine has full FDA approval with age- and risk-level-based restrictions, while Moderna's COVID-19 vaccines have full licensure across broader age groups.</p><h2 class="st-heading-2"><strong>How Did Stocktwits Users React?</strong></h2><p>On Stocktwits, retail sentiment toward Moderna was ‘extremely bullish’ amid ‘extremely high’ message volume, with watchers up 3% and message activity more than doubling over the past 12 months.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/mrna_ss_png_124327497e.webp" alt="mrna ss.png" width="971" height="142"><figcaption>MRNA sentiment and message volume as of January 21 | Source: Stocktwits</figcaption></figure><p>On the other hand, retail sentiment toward Novavax was ‘extremely bullish’ amid ‘extremely high’ message volume, with watchers up 5% and message activity surging more than 600% over the past 12 months.</p><figure class="image"><img src="https://news.stocktwits-cdn.com/nvax_ss_png_ec285c2653.webp" alt="nvax ss.png" width="969" height="138"><figcaption>NVAX sentiment and message volume as of January 21 | Source: Stocktwits</figcaption></figure><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

 In this photo illustration vials of vaccines for coronavirus (COVID-19). Vaccines from left to right, Moderna, Bimervax, Comirnaty and Pfizer BioNTech. (Photo Illustration by Marcos del Mazo/LightRocket via Getty Images)

MRNA Vs NVAX: Which Vaccine Stock Is Wall Street More Bullish On Right Now?

Regulatory uncertainty remains a common factor for both companies following an FDA memo that raised concerns about vaccine safety.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

With earnings season underway and rate-cut expectations shifting, the next move in the S&P 500 could set the tone for 2026. Are bulls still in control, or is volatility about to pick up? Cast your vote.

Stocktwits

Stocktwits Polls

Novavax Inc

The FDA's refusal to review Moderna's mRNA flu vaccine application creates a significant opportunity for Novavax's protein-based platform in the market.

Speculation intensifies regarding major partnership agreements or a potential acquisition by Big Pharma, with companies like Pfizer and Sanofi frequently mentioned.

Traders are intensely watching for a short squeeze as institutional buying, coupled with positive catalysts, could force short sellers to cover positions at higher prices.

Bank of America's recent 13G filing revealing a new significant stake of over 5% suggests major institutional confidence and accumulation at current price levels.

Current Price	$8.49
Prev Close	$8.97
Open	$8.97
Dividend Yield	0.00%
50-Day Moving Average	$7.69
Beta	1.46
Avg. Volume	6.45M
PE Ratio	5.07

52-Week High	$10.64
52-Week Low	$5.01
Market Capitalization	$1.46B
EPS (Annual)	-$1.23
Price to Book	-9.30
Revenue Per Employee	$716,556.72

NVAX
Novavax Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest NVAX News

NVAXNovavax Inc